A more recent addition to my transformational technologies portfolio, Medarex (NASDAQ:MEDX), has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck (NYSE:MRK) for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in milestones as well as royalties.

As the markets would tell it, the swine flu epidemic is little more than a tempest in a teacup. But, sad to say, the danger here remains far greater than it seems…